Evidence map›Paper›PMID 32999313›Full record

ArticleScientific reports2020

Deciphering heterogeneity of septic shock patients using immune functional assays: a proof of concept study.

Chloé Albert Vega, Guy Oriol, François Bartolo, Jonathan Lopez, Alexandre Pachot, Thomas Rimmelé, Fabienne Venet, Véronique Leray, Guillaume Monneret, Benjamin Delwarde and 4 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Chloé Albert VegaLaboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Joint Research Unit Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Bâtiment 3F, Pierre-Bénite, 69495, Lyon, France. chloe.albertvega@gmail.com.
Guy OriolLaboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Joint Research Unit Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Bâtiment 3F, Pierre-Bénite, 69495, Lyon, France.
François BartoloLaboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Joint Research Unit Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Bâtiment 3F, Pierre-Bénite, 69495, Lyon, France.
Jonathan LopezHospices Civils de Lyon - Plateforme de Recherche de Transfert en Oncologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, 69495, Lyon, France.
Alexandre PachotOpen Innovation and Partnerships Department, bioMérieux S.A., Marcy l'Étoile, France.
Thomas RimmeléEA 7426 Pathophysiology of Injury-Induced Immunosuppression, PI3, Claude Bernard Lyon 1 University-bioMérieux-Hospices Civils de Lyon, Hôpital Edouard Herriot, 69437, Lyon, France.
Fabienne VenetEA 7426 Pathophysiology of Injury-Induced Immunosuppression, PI3, Claude Bernard Lyon 1 University-bioMérieux-Hospices Civils de Lyon, Hôpital Edouard Herriot, 69437, Lyon, France.
Véronique LerayAnesthesia and Critical Care Medicine Department, Hôpital Edouard Herriot, Hospices Civils de Lyon, 69437, Lyon, France.
Guillaume MonneretEA 7426 Pathophysiology of Injury-Induced Immunosuppression, PI3, Claude Bernard Lyon 1 University-bioMérieux-Hospices Civils de Lyon, Hôpital Edouard Herriot, 69437, Lyon, France.
Benjamin DelwardeAnesthesia and Critical Care Medicine Department, Hôpital Edouard Herriot, Hospices Civils de Lyon, 69437, Lyon, France.
Karen Brengel-PesceLaboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Joint Research Unit Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Bâtiment 3F, Pierre-Bénite, 69495, Lyon, France.
Julien TextorisOpen Innovation and Partnerships Department, bioMérieux S.A., Marcy l'Étoile, France.
François Mallet *Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Joint Research Unit Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Bâtiment 3F, Pierre-Bénite, 69495, Lyon, France.
Sophie Trouillet-Assant *Laboratoire Commun de Recherche Hospices Civils de Lyon-bioMérieux, Joint Research Unit Hospices Civils de Lyon-bioMérieux, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Bâtiment 3F, Pierre-Bénite, 69495, Lyon, France.
Hospices Civils de Lyon · FRUniversité Claude Bernard Lyon 1 · FRbioMérieux (France) · FR

Funding

Marie Curie 676129
6 · The paper itself

Abstract

The complexity of sepsis pathophysiology hinders patient management and therapeutic decisions. In this proof-of-concept study we characterised the underlying host immune response alterations using a standardised immune functional assay (IFA) in order to stratify a sepsis population. In septic shock patients, ex vivo LPS and SEB stimulations modulated, respectively, 5.3% (1/19) and 57.1% (12/21) of the pathways modulated in healthy volunteers (HV), highlighting deeper alterations induced by LPS than by SEB. SEB-based clustering, identified 3 severity-based groups of septic patients significantly different regarding mHLA-DR expression and TNFα level post-LPS, as well as 28-day mortality, and nosocomial infections. Combining the results from two independent cohorts gathering 20 HV and 60 patients, 1 cluster grouped all HV with 12% of patients. The second cluster grouped 42% of patients and contained all non-survivors. The third cluster grouped 46% of patients, including 78% of those with nosocomial infections. The molecular features of these clusters indicated a distinctive contribution of previously described genes defining a "healthy-immune response" and a "sepsis-related host response". The third cluster was characterised by potential immune recovery that underlines the possible added value of SEB-based IFA to capture the sepsis immune response and contribute to personalised management.

Indexed as

AgedBiomarkersCross InfectionEnterotoxinsFemaleGene ExpressionGene Expression ProfilingHLA-DR AntigensHumansLipopolysaccharidesMaleMiddle AgedMonocytesProof of Concept StudySepsisShock, SepticBiomarkersenterotoxin B, staphylococcalEnterotoxinsHLA-DR AntigensLipopolysaccharidesTNF protein, humanTumor Necrosis Factor-alpha

Identifiers

PMID32999313
PMCPMC7527338
OpenAlexW3091517482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.